Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q02790

UPID:
FKBP4_HUMAN

ALTERNATIVE NAMES:
51 kDa FK506-binding protein; 52 kDa FK506-binding protein; 59 kDa immunophilin; FK506-binding protein 4; FKBP59; HSP-binding immunophilin; Immunophilin FKBP52; Rotamase

ALTERNATIVE UPACC:
Q02790; D3DUQ1; Q9UCP1; Q9UCV7

BACKGROUND:
The protein Peptidyl-prolyl cis-trans isomerase FKBP4, also referred to as FKBP52, is a multifunctional immunophilin involved in the regulation of steroid receptors and neuronal growth. Its ability to inhibit MAPT/TAU's promotion of microtubule assembly and its protective role against oxidative stress in mitochondria are of significant interest in cellular biology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Peptidyl-prolyl cis-trans isomerase FKBP4 offers a promising pathway to developing novel therapeutic approaches. Given its critical role in cellular trafficking, neuronal development, and stress response, targeting FKBP52 could lead to breakthroughs in treating a range of disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.